Intermountain Health Care
Intermountain Health Care sponsors 85 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 55 completed. 14 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pediatric Infectious Disease, with 2 trials.
Trial Pipeline
85 total, page 2 of 2
Systems Biology Approach to Cognitive Impairment After SepsiS
NCT03015584
Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)
NCT03226366
Vagus Nerve Injury Post Radiofrequency Catheter Ablation for Atrial Fibrillation
NCT02562404
Echo vs. EGDT in Severe Sepsis and Septic Shock
NCT02354742
Patient Ambulation in Post-Op Recovery
NCT02528669
Promoting Patient-Centered Care Through a Heart Failure Simulation Study
NCT01917188
Intermountain Risk Score and Trauma
NCT02011412
The Use of Ranolazine for Atrial Fibrillation and Diastolic Heart Failure
NCT01887353
The Fasting II Study
NCT01792986
Outpatient Treatment of Low-risk Pulmonary Embolism
NCT02355548
Hypobaria and Traumatic Pneumothorax
NCT01670942
Test of Chamber Pressure to Divers and Chamber Attendants
NCT01430325
Methadone Monitoring for Insights Into Adverse Events
NCT01191242
Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use
NCT01143259
Expression of Longevity Genes in Response to Extended Fasting
NCT01059760
The Value of Traction in the Treatment of Cervical Radiculopathy
NCT00979108
The Value of Traction in Treatment of Lumbar Radiculopathy
NCT00942227
Standardizing Management of Patients With Low Back Pain in Primary Care and Physical Therapy
NCT00769626
Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin
NCT00927862
Outcome Following Carbon Monoxide Poisoning in Children
NCT01059708
Functional and Anatomical Magnetic Resonance Imaging (MRI) of Chronic Brain Injury and Hyperbaric Oxygen (HBO2) Study Subjects
NCT01126515
The Purple Grape Juice Study
NCT00551746
One vs. Three Hyperbaric Oxygen Treatments for Acute Carbon Monoxide Poisoning
NCT00465855
Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using CT Angiography, Following Core 64
NCT00488033
Response to Medication Registry
NCT02593916
Exercise Treatment of Mild-Stage Probable Alzheimer's Disease
NCT00403507
Rosiglitazone and Metformin: Outcomes Trial in Nondiabetic Patients With Stable Coronary Syndromes (Romance) Pilot Study
NCT00343395
A Pharmacogenetic Study of Warfarin Dosing, "The COUMA-GEN Study"
NCT00334464
Single Comprehensive Ultrasound to Rule Out DVT in High-risk Patients
NCT00333697
Clopidogrel and Aspirin Together: The Effect on C-Reactive Protein Trial
NCT00343876
SAFEstart Feeding Intolerance Study Phase II
NCT00331201
ETCare: Safety and Preliminary Efficacy Trial
NCT01688440
The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)
NCT00343499
Hyperbaric Oxygen Therapy in Chronic Stable Brain Injury
NCT00830453
Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study
NCT00309712
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
| Phase 3 | 4 |
| Phase 4 | 10 |
What the Pipeline for Intermountain Health Care Shows
According to the ClinicalTrials.gov registry, Intermountain Health Care is linked to 85 US clinical trials across every stage of research activity. Of those, 11 studies are currently recruiting, about 13% of the sponsor's indexed portfolio, and 55 are already marked complete, representing roughly 65% of the total.
The phase mix for Intermountain Health Care reports 14 late-stage studies (Phase 3 and Phase 4 combined) and 8 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Intermountain Health Care is Pediatric Infectious Disease with 2 linked trials, and 9 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.